ITRM Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Iterum Therapeutics PLC (ITRM) is not a strong buy for a beginner, long-term investor at this time. The stock lacks positive trading signals, has weak financial performance, and no recent positive catalysts or news. Given the bearish technical indicators and lack of significant upward momentum, it is better to hold off on investing in this stock.
The MACD is slightly positive but contracting, indicating weak momentum. RSI is neutral at 37.586, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). Key support is at 0.278, and resistance is at 0.35. Overall, the technical indicators suggest a bearish trend.
NULL. There is no recent news or significant trading trends from hedge funds or insiders.
Bearish technical indicators, weak financial performance, and no recent positive news or trading trends.
In Q3 2025, revenue remained flat at $390,000 YoY. Net income improved by 47.34% YoY but remains negative at -$8,979,000. EPS dropped by 33.33% YoY to -0.2. Gross margin is 5.38%, with no YoY growth. Overall, the financials show minimal improvement and remain weak.
No recent analyst rating or price target changes available.
